{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:41Z","timestamp":1787020121850,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13013-2","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:15:33Z","timestamp":1773047733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of dolutegravir-based therapy in achieving virological suppression in PLHIV in low- and middle-income countries: real-world evidence from a large clinical cohort in Cameroon"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-8635","authenticated-orcid":false,"given":"Carine","family":"Tadenfok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-2763","authenticated-orcid":false,"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8768-2371","authenticated-orcid":false,"given":"Ezechiel Ngoufack Jagni","family":"Semengue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonella","family":"Mossiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Oyie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Noumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Ngia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6870-7366","authenticated-orcid":false,"given":"Grace Angong","family":"Beloumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7903-6182","authenticated-orcid":false,"given":"Sandrine Claire","family":"Djupsa Ndjeyep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-8661","authenticated-orcid":false,"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-1436","authenticated-orcid":false,"given":"Collins","family":"Chenwi Ambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2381-4299","authenticated-orcid":false,"given":"Aude Christelle","family":"Ka\u2019e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-7508","authenticated-orcid":false,"given":"Desire","family":"Takou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0916-0142","authenticated-orcid":false,"given":"Derrick Tambe Ayuk","family":"Ngwese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4294-9310","authenticated-orcid":false,"given":"Tatiana Tekoh","family":"Anim-keng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lum","family":"Forgwei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline","family":"Kengne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-683X","authenticated-orcid":false,"given":"Bouba","family":"Yagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-6748","authenticated-orcid":false,"given":"Elise","family":"Elong Lobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Feukeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-5063","authenticated-orcid":false,"given":"Rogers Ajeh","family":"Awoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2300-0748","authenticated-orcid":false,"given":"Anne-Cecile ZK","family":"Bissek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-4370","authenticated-orcid":false,"given":"Marius","family":"Vouking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-9271","authenticated-orcid":false,"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-3428","authenticated-orcid":false,"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-5388","authenticated-orcid":false,"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-6205","authenticated-orcid":false,"given":"Charles","family":"Kouanfack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-0159","authenticated-orcid":false,"given":"Celine","family":"Nkenfou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"13013_CR1","unstructured":"UNAIDS. The path that ends AIDS: 2023 UNAIDS Global AIDS Update. Geneva: UNAIDS; 2023. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2023-unaids-global-aids-update_en.pdf."},{"key":"13013_CR2","volume-title":"Rapport annuel des activit\u00e9s de lutte contre le VIH\/Sida au Cameroun, 2023","author":"Comit\u00e9 National de Lutte contre le Sida (CNLS)","year":"2024","unstructured":"Comit\u00e9 National de Lutte contre le Sida (CNLS). Rapport annuel des activit\u00e9s de lutte contre le VIH\/Sida au Cameroun, 2023. Yaound\u00e9: CNLS; 2024. Disponible \u00e0 :. https:\/\/www.cnls.cm\/uploads\/docs\/2025-01-02-rapport-annuel-2023-vih-draft-final-latest.pdf."},{"key":"13013_CR3","doi-asserted-by":"crossref","unstructured":"Cameroon Factsheet. Country factsheets Cameroon 2022 Change.pdf. 2022.","DOI":"10.5089\/9798400227264.002"},{"key":"13013_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12879-024-09202-6","volume":"24","author":"N Hurbans","year":"2024","unstructured":"Hurbans N, Naidoo P. Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study. BMC Infect Dis. 2024;24:343. https:\/\/doi.org\/10.1186\/s12879-024-09202-6.","journal-title":"BMC Infect Dis"},{"key":"13013_CR5","doi-asserted-by":"crossref","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis mars. 2018;18(3):346\u201355.","DOI":"10.1016\/S1473-3099(17)30702-8"},{"key":"13013_CR6","unstructured":"World Health Organization (WHO). WHO Model List of Essential Medicines \u2013 2021. Geneva: WHO. 2021. Licence: CC BY-NC-SA 3.0 IGO. Report No.: WHO\/MHP\/HPS\/EML\/2021.02. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/345533"},{"issue":"2","key":"13013_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","volume":"19","author":"J Hemelaar","year":"2019","unstructured":"Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, et al. Global and regional molecular epidemiology of HIV-1, 1990\u20132015: a systematic review, global survey, and trend analysis. Lancet Infect Dis f\u00e9vr. 2019;19(2):143\u201355.","journal-title":"Lancet Infect Dis f\u00e9vr"},{"key":"13013_CR8","unstructured":"CAMPHIA Study Group; Cameroon Ministry of Public Health; CDC. ICAP at Columbia University. Cameroon Population-based HIV Impact Assessment (CAMPHIA) 2017\u20132018: Final Report. Yaound\u00e9, Cameroon; 2019."},{"key":"13013_CR9","unstructured":"World Health Organization. HIV Drug Resistance Report 2024. Geneva: WHO. 2024. Report No.: WHO\/HIV\/2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240095139"},{"key":"13013_CR10","doi-asserted-by":"crossref","unstructured":"Billong SC, Penda CI, Fokam J, Mvilongo AE, Fodjo R, Messeh A et al. Profil national des indicateurs d\u00b4alerte pr\u00e9coce de la pharmaco-r\u00e9sistance du VIH au Cameroun. Pan Afr Med J [Internet]. 2020 [cit\u00e9 30 mars 2023];37. Disponible sur: https:\/\/www.panafrican-med-journal.com\/content\/article\/37\/374\/full","DOI":"10.11604\/pamj.2020.37.374.17649"},{"issue":"22","key":"13013_CR11","doi-asserted-by":"publisher","first-page":"e33897","DOI":"10.1097\/MD.0000000000033897","volume":"102","author":"PR Mbouyap","year":"2023","unstructured":"Mbouyap PR, Fokam J, Ngoufack Jagni Semengue E, Mossiang L, Takou D, Ambe Chenwi C, et al. HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon. Med (Baltimore) 2 juin. 2023;102(22):e33897.","journal-title":"Med (Baltimore) 2 juin"},{"issue":"4","key":"13013_CR12","doi-asserted-by":"publisher","first-page":"e1001810","DOI":"10.1371\/journal.pmed.1001810","volume":"12","author":"SY Rhee","year":"2015","unstructured":"Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med avr. 2015;12(4):e1001810.","journal-title":"PLoS Med avr"},{"issue":"2","key":"13013_CR13","doi-asserted-by":"publisher","first-page":"ofv158","DOI":"10.1093\/ofid\/ofv158","volume":"3","author":"A Huang","year":"2016","unstructured":"Huang A, Hogan JW, Luo X, DeLong A, Saravanan S, Wu Y, et al. Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes. Open Forum Infect Dis avr. 2016;3(2):ofv158.","journal-title":"Open Forum Infect Dis avr"},{"key":"13013_CR14","unstructured":"World Health Organization. HIV Drug Resistance Report 2019, Geneva. WHO; 2019. Report No.: WHO\/CDS\/HIV\/19.21. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241516466"},{"key":"13013_CR15","doi-asserted-by":"crossref","unstructured":"Semengue ENJ, Fokam J, Etame NK, Molimbou E, Chenwi CA, Takou D et al. Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based First-LINE ART in cameroon: an evidence of a successful transition model. Viruses. 21 d\u00e9c. 2022;15(1):18.","DOI":"10.3390\/v15010018"},{"key":"13013_CR16","doi-asserted-by":"crossref","unstructured":"Mehari EA, Muche EA, Gonete KA. Virological suppression and its associated factors of dolutegravir based regimen in a resource-limited setting: an observational retrospective study in ethiopia. HIVAIDS - Res Palliat Care juin 2021;13:709\u201317.","DOI":"10.2147\/HIV.S316776"},{"key":"13013_CR17","doi-asserted-by":"crossref","unstructured":"Andersson E, Nordquist A, Esbj\u00f6rnsson J, Flamholc L, Gissl\u00e9n M, Hejdeman B et al. Increase in transmitted drug resistance in migrants from Sub-Saharan Africa diagnosed with HIV-1 in Sweden. AIDS. 24 avr. 2018;32(7):877\u201384.","DOI":"10.1097\/QAD.0000000000001763"},{"key":"13013_CR18","volume-title":"Global Action Plan on HIV Drug Resistance 2023\u20132030","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global Action Plan on HIV Drug Resistance 2023\u20132030. Geneva: WHO; 2023."},{"key":"13013_CR19","doi-asserted-by":"crossref","unstructured":"Takou D, Fokam J, Teto G, Santoro MM, Ceccherini-Silberstein F, Nanfack AJ et al. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. BMC Infect Dis. 12 mars. 2019;19(1):246.","DOI":"10.1186\/s12879-019-3871-0"},{"issue":"6","key":"13013_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00705-020-04606-6","volume":"165","author":"Z Yang","year":"2020","unstructured":"Yang Z, Wei S, Liu J, Piao J, Xu L, Sun Y, et al. Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017\u20132019). Arch Virol 1 juin. 2020;165(6):1453\u201361.","journal-title":"Arch Virol 1 juin"},{"issue":"2","key":"13013_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/v8020048","volume":"8","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Rojas S\u00e1nchez P, Rhee SY, Shafer RW. Genetic Variability of HIV-1 for Drug Resistance Assay Development. Viruses 11 f\u00e9vr. 2016;8(2):48.","journal-title":"Viruses 11 f\u00e9vr"},{"key":"13013_CR22","unstructured":"H\u00f4pital. Central de Yaound\u00e9 | Yaound\u00e9 [Internet]. [cit\u00e9 9 mars 2025]. Disponible sur: https:\/\/fr-fr.facebook.com\/hopicentral"},{"key":"13013_CR23","unstructured":"World Health Organization. HIV Drug Resistance Report 2017 \u2013 Update 2018. Geneva: WHO. 2018. Report No.: WHO\/CDS\/HIV\/18.51. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-HIV-18.51"},{"issue":"7","key":"13013_CR24","first-page":"1458","volume":"15","author":"J Fokam","year":"2023","unstructured":"Fokam J, Chenwi CA, Tala V, Takou D, Santoro MM, Teto G, et al. Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens. Viruses 28 juin. 2023;15(7):1458.","journal-title":"Viruses 28 juin"},{"key":"13013_CR25","unstructured":"HIVdb P. Mutations analysis - stanford coronavirus antiviral & resistance database (CoVDB) [Internet]. [cit\u00e9 28 mai 2024]. Disponible sur: https:\/\/hivdb.stanford.edu\/hivdb\/by-patterns\/"},{"issue":"7","key":"13013_CR26","doi-asserted-by":"publisher","first-page":"e0235958","DOI":"10.1371\/journal.pone.0235958","volume":"15","author":"J Fokam","year":"2020","unstructured":"Fokam J, Takou D, Teto G, Nforbih SE, Kome OP, Santoro MM, et al. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon. Ceccherini-Silberstein F, \u00e9diteur. PLOS ONE 21 juill. 2020;15(7):e0235958.","journal-title":"PLOS ONE 21 juill"},{"issue":"9","key":"13013_CR27","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/jac\/dky221","volume":"73","author":"GF Tchouwa","year":"2018","unstructured":"Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, et al. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. J Antimicrob Chemother 1 sept. 2018;73(9):2468\u201374.","journal-title":"J Antimicrob Chemother 1 sept"},{"issue":"Suppl 1","key":"13013_CR28","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/QAD.0000000000001888","volume":"32","author":"P Patel","year":"2018","unstructured":"Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabuddhe VV, Peprah E, et al. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. AIDS Lond Engl 1 juill. 2018;32(Suppl 1):S5\u201320.","journal-title":"AIDS Lond Engl 1 juill"},{"issue":"6","key":"13013_CR29","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/aid.2020.0196","volume":"37","author":"D Di Carlo","year":"2021","unstructured":"Di Carlo D, Falasca F, Palermo E, Mezzaroma I, Fimiani C, Siccardi G, et al. Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. AIDS Res Hum Retroviruses juin. 2021;37(6):478\u201385.","journal-title":"AIDS Res Hum Retroviruses juin"},{"key":"13013_CR30","unstructured":"HIV.gov [Internet]. [cit\u00e9 27 ao\u00fbt 2025]. Youth with HIV Less Likely Than Adults to Achieve Viral Suppression. Disponible sur: https:\/\/www.hiv.gov\/blog\/youth-hiv-less-likely-adults-achieve-viral-suppression"},{"key":"13013_CR31","doi-asserted-by":"publisher","unstructured":"Determinants of viral suppression among adolescents on antiretroviral treatment in Ehlanzeni district. South Africa: a cross-sectional analysis | AIDS Research and Therapy | Full Text [Internet]. [cit\u00e9 27 ao\u00fbt 2025]. Disponible sur: https:\/\/aidsrestherapy.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12981-021-00391-7","DOI":"10.1186\/s12981-021-00391-7"},{"key":"13013_CR32","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1186\/s12879-025-11647-2","volume":"25","author":"VO Moro","year":"2025","unstructured":"Moro VO, Ssenkusu JM, Kiweewa FM. Correlates of virological non-suppression among children and adolescents aged 5\u201319 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study. BMC Infect Dis. 2025;25:1438. https:\/\/doi.org\/10.1186\/s12879-025-11647-2.","journal-title":"BMC Infect Dis"},{"key":"13013_CR33","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1186\/s12879-025-11639-2","volume":"25","author":"F Ciccacci","year":"2025","unstructured":"Ciccacci F, Doro Altan AM, Majid N, et al. HIV Dolutegravir resistance and multiclass failure in Mozambique: findings from a real-world cohort. BMC Infect Dis. 2025;25:1210. https:\/\/doi.org\/10.1186\/s12879-025-11639-2.","journal-title":"BMC Infect Dis"},{"key":"13013_CR34","doi-asserted-by":"crossref","unstructured":"Kantor R, DeLong A, Schreier L, Reitsma M, Kemboi E, Orido M, et al. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya. AIDS. 2018 Nov;13(17):2485\u201396.","DOI":"10.1097\/QAD.0000000000001964"},{"key":"13013_CR35","doi-asserted-by":"crossref","unstructured":"VazP, Buck WC, Bhatt N, Bila D, Auld A, Houston J et al. Compromise of second-line antiretroviral therapy due to high rates of human immunodeficiency virus drug resistance in mozambican treatment-experienced children with virologic failure. J Pediatr Infect Dis Soc [Internet]. 25 oct 2018 [cit\u00e9 22 mars 2023]; Disponible sur: https:\/\/academic.oup.com\/jpids\/advance-article\/doi\/10.1093\/jpids\/piy102\/5144838","DOI":"10.1093\/jpids\/piy102"},{"key":"13013_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ijid.2020.12.085","volume":"104","author":"PJ Palumbo","year":"2021","unstructured":"Palumbo PJ, Zhang Y, Clarke W, Breaud A, Sivay M, Cummings V, et al. Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075. Int J Infect Dis mars. 2021;104:465\u201370.","journal-title":"Int J Infect Dis mars"},{"key":"13013_CR37","doi-asserted-by":"crossref","unstructured":"Hauser A, Hofmann A, Meixenberger K, Altmann B, Hanke K, Bremer V, et al. Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: results from the national molecular surveillance of new HIV-diagnoses. PLoS One. 2018 Nov;13(11):e0206234.","DOI":"10.1371\/journal.pone.0206234"},{"issue":"6","key":"13013_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cid\/ciab583","volume":"74","author":"RP McClung","year":"2022","unstructured":"McClung RP, Oster AM, Ocfemia MCB, Saduvala N, Heneine W, Johnson JA, et al. Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014\u20132018. Clin Infect Dis 23 mars. 2022;74(6):1055\u201362.","journal-title":"Clin Infect Dis 23 mars"},{"key":"13013_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmicb.2019.00020","volume":"10","author":"TSO Tanaka","year":"2019","unstructured":"Tanaka TSO, Leite TF, Freitas SZ, Cesar GA, De Rezende GR, Lindenberg ADSC, et al. HIV-1 Molecular Epidemiology, Transmission Clusters and Transmitted Drug Resistance Mutations in Central Brazil. Front Microbiol 31 janv. 2019;10:20.","journal-title":"Front Microbiol 31 janv"},{"issue":"9","key":"13013_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019;381(9):803\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1902824. Epub 2019 Jul 24. PMID: 31339677. Bas du formulaire.","journal-title":"N Engl J Med"},{"issue":"4","key":"13013_CR41","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/QAI.0000000000002475","volume":"85","author":"F Jean Louis","year":"2020","unstructured":"Jean Louis F, Domercant JW, Ignacio C, Gianella S, Galbaud G, Leonard M, et al. High Prevalence of HIV-1 Drug Resistance and Dynamics of Transmission Among High-Risk Populations in Port-au-Prince, Haiti. JAIDS J Acquir Immune Defic Syndr 1 d\u00e9c. 2020;85(4):416\u201322.","journal-title":"JAIDS J Acquir Immune Defic Syndr 1 d\u00e9c"},{"key":"13013_CR42","doi-asserted-by":"publisher","first-page":"589937","DOI":"10.3389\/fmicb.2020.589937","volume":"11","author":"\u00c1MDCE Silva","year":"2020","unstructured":"Silva \u00c1MDCE, Reis MNDG, Marinho TA, Freitas NRD, Teles SA, Matos MADD, et al. Epidemiological and Molecular Characteristics of HIV-1 Infection in a Sample of Men Who Have Sex With Men in Brazil: Phylogeography of Major Subtype B and F1 Transmission Clusters. Front Microbiol 27 nov. 2020;11:589937.","journal-title":"Front Microbiol 27 nov"},{"issue":"3","key":"13013_CR43","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1093\/cid\/ciac660","volume":"76","author":"NJ Dharan","year":"2023","unstructured":"Dharan NJ, Jin F, Vaccher S, Bavinton B, Yeung B, Guy R, et al. Characteristics of Human Immunodeficiency Virus (HIV) Seroconversions in a Large Prospective Implementation Cohort Study of Oral HIV Preexposure Prophylaxis in Men Who Have Sex with Men (EPIC-NSW). Clin Infect Dis 8 f\u00e9vr. 2023;76(3):e622\u20138.","journal-title":"Clin Infect Dis 8 f\u00e9vr"},{"issue":"5","key":"13013_CR44","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jac\/dkz011","volume":"74","author":"L Assoumou","year":"2019","unstructured":"Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, et al. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015\/2016 in France. J Antimicrob Chemother 1 mai. 2019;74(5):1417\u201324.","journal-title":"J Antimicrob Chemother 1 mai"},{"key":"13013_CR45","doi-asserted-by":"crossref","unstructured":"Zhang Y, Fogel JM, Guo X, Clarke W, Breaud A, Cummings V, et al. Antiretroviral drug use and HIV drug resistance among MSM and transgender women in Sub-Saharan Africa. AIDS. 2018 Jun 19;32(10):1301\u20136.","DOI":"10.1097\/QAD.0000000000001839"},{"issue":"9","key":"13013_CR46","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1089\/mdr.2019.0344","volume":"26","author":"CM Gonz\u00e1lez-Domenech","year":"2020","unstructured":"Gonz\u00e1lez-Domenech CM, Sena-Corrales G, Viciana-Ramos I, Palacios-Mu\u00f1oz R, Mora-Navas L, Clavijo-Frutos E, et al. High Prevalence of Sequences Included in Transmission Clusters Within Newly Diagnosed HIV-1 Patients in Southern Spain (2004\u20132015). Microb Drug Resist 1 sept. 2020;26(9):1090\u20137.","journal-title":"Microb Drug Resist 1 sept"},{"key":"13013_CR47","doi-asserted-by":"crossref","unstructured":"Wang X, Liu X, Li F, Zhou H, Li J, Wang Y, et al. Epidemiological surveillance of HIV-1 transmitted drug resistance among newly diagnosed individuals in Shijiazhuang, Northern China, 2014\u20132015. PLoS One. 2018 Jun 5;13(6):e0198005.","DOI":"10.1371\/journal.pone.0198005"},{"key":"13013_CR48","unstructured":"Pabo W, Fokam J, Njume D, Takou D, Santoro M, Nyassa R, Chenwi C, Mpouel M, Beloumou G, Ngoufack E, Nka A, Ka\u2019e A, Teto G, et al. HIV-1 subtype diversity and immuno-virological outcomes among adolescents failing antiretroviral therapy in Cameroon: a cohort study. PLoS One. 2023 Oct;25:e10.1371."},{"issue":"5","key":"13013_CR49","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1128\/JVI.02302-15","volume":"90","author":"M Tongo","year":"2015","unstructured":"Tongo M, Dorfman JR, Martin DP. High Degree of HIV-1 Group M (HIV-1\u00a0M) Genetic Diversity within Circulating Recombinant Forms: Insight into the Early Events of HIV-1\u00a0M Evolution. J Virol 9 d\u00e9c. 2015;90(5):2221\u20139.","journal-title":"J Virol 9 d\u00e9c"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13013-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13013-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13013-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:26:56Z","timestamp":1776252416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13013-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13013"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13013-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8290769\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Following the ethical principles of the Helsinki Declaration, ethical clearance was obtained from the Institutional Ethics Committee for Research on Human Health, N\n                      \u00b02023\/022045\/CEIRSH\/ESS\/BC.\n                      Authorizations from host structures involved in the study were obtained before the beginning of the study. A written informed consent was obtained from each participant before enrollment. The various exams were free-of charge to the participants, and the results were given to the physicians to optimize the treatment. We used a specific identifier, to insured confidentiality; and data were protected by using a password on computers and phones.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"765"}}